Edaravone: A new drug approved for ALS.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 29100067.
- Also identified by DOI 10.1016/j.cell.2017.10.011.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Amyotrophic lateral sclerosis (ALS) is a progressive, adult onset neurodegenerative disease that is always fatal. The history of ALS drug discovery is fraught with many stops and starts. It took 22 years after the FDA approval of the anti-excitotoxic drug Riluzole before another drug was found to be effective in altering ALS progression: the anti-oxidant Edaravone.
Medical subject headings
- Amyotrophic Lateral Sclerosis
- Antipyrine
- Drug Approval
- Excitatory Amino Acid Antagonists